Prostate Cancer

The European Association of Urology has recently supported the development of expert groups of young academic urologists with the purpose of boosting research activity in some critical areas of urology and improving academic collaboration among different centres in Europe.

The expert groups aim at scientific cooperation and manuscript preparation, study design or other scientific output. The Prostate Cancer Working Group

is open to European non-urologists with an interest in the management of prostate cancer in order to fully cover the disease in a multidisciplinary fashion.

Aims of the Prostate Cancer Working Group

The chief aim of our working group is to bring young academic urologists practicing in Europe with a chief interest in the management of prostate cancer together and promote active collaboration between them.

Our group wishes to include also young academic non-urologists (i.e. radiologists, radiation oncologists and medical oncologists) practicing in Europe with a chief interest in the management of prostate cancer, in order to approach the disease from many different professional standpoints. Another goal is to merge already existing retrospective multi-institutional databases and create prospective multi-institutional databases and registry studies. With this regard, we feel it is important to establish a close collaboration with already formed groups of investigators (e.g. EMPaCT Research Group).

Furthermore, our group aims at exploring current practice patterns of European physicians on timely and controversial topics related to prostate cancer management through web-based surveys. At the EAU level, our group wishes to actively participate in the revision process of the EAU Guideline on Prostate Cancer. Last but not least, we wish to create a group of young “key opinion leaders” who can collaborate with committees of scientific societies and international congresses at different levels (board members, organisers, speakers).

Ongoing projects and plans for the future

Original studies:

  • Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multinational, multi-institutional study of 2323 patients.
  • Impact of separate versus en bloc extended pelvic lymph node dissection on nodal yield at the time of radical prostatectomy.
  • Prospective, possibly randomised, multi-institutional study including open/laparoscopic/ robotic cases.
  • Assessment of “severe complications” after RP (death, pulmonary embolism, thrombosis, pneumonia, GI complications) vs. RT (GU, GI, cardiovascular due to ADT, secondary malignancies).
  • Population-based or multi-institutional study with matched-pair analysis.
  • Comparison of prostate cancer detection rate between TRUS-guided prostate biopsy including systematic transition zone biopsies and MRI-targeted prostate biopsy.
  • Prospective multi-institutional study.
  • Analysis of Gleason score migration from 3+3 to higher after the release of the ISUP modified Gleason grading system in 2005. Implications for patient selection for active surveillance.
  • Population-based or multi-institutional study.
  • Impact of radical treatment vs. conservative treatment on overall and cancer-specific survival in elderly patients (>70 years). Implications for screening.
  • Population-based or multi-institutional study.

Review articles:

  • The role of tertiary Gleason pattern in the management of patients with clinically localized prostate cancer: a systematic review of the literature.
  • The role of neuroendocrine differentiation in patients with prostate cancer: a systematic review of the literature.
  • Saturation and extended biopsies: indications and advantages.
  • Metastasis-directed salvage treatment for regional and distant disease recurrence after curative treatment for prostate cancer: a systematic review of the literature.
  • Role of local treatment in advanced prostate cancer: a systematic review of the literature.
  • Is there a role for pelvic lymph node treatment in patients with clinically node-negative intermediate- and high-risk prostate cancer? A systematic review of the literature.
  • The role of MRI in the management of prostate cancer: a systematic review of the literature.
  • Can clinically significant prostate cancer be detected with functional MRI? A systematic review of the literature.
  • The role of USPIO-enhanced MRI in the detection of nodal metastases of urological malignancies: a systematic review and meta-analysis.
  • Treatment decisions in patients with intermediate and high-risk prostate cancer and significant genitourinary symptoms: a systematic review.

Web-based surveys:

  • Current trends in management of high-risk prostate cancer across Europe: results of a web-based survey.
  • Prostate biopsy (indications, anaesthesia, technique, use of any imaging other than conventional TRUS).
  • Active surveillance (inclusion criteria, definition of progression and evaluation of its predictors, active treatment, quality of life assessment).
  • Management of CRPC (definition, first-line, second-line, definition of progression, imaging modality used, follow-up).

Board YAU Working Group Prostate Cancer

G. Ploussard

Toulouse (FR)
Chairman

P.J.L. De Visschere

Ghent (BE)
Member

I. Tsaur

Mainz (DE)
Member

D. Tilki

Hamburg (DE)
Member

P. Ost

Ghent (BE)
Member

G. Gandaglia

Milan (IT)
Member

R.C.N. Van Den Bergh

Utrecht (NL)
Member

C. Surcel

Bucharest (RO)
Member

A. Kretschmer

Munich (DE)
Member

I. Heidegger

Innsbruck (AT)
Member

R. Mathieu

Tinteniac (FR)
Member

M. Valerio

Lausanne (CH)
Member

H. Borgmann

Mainz (DE)
Member